Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2013European Journal of CancerOpen Access

Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RARichard A. AndersonBoston UniversityMRMikkel RosendahlCopenhagen University HospitalTKTom KelseyUniversity of St Andrews

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Anderson et al. (2013) studied this question.

synapsesocial.com/papers/69dd40fcac7bdbc6c71013b0https://doi.org/10.1016/j.ejca.2013.07.014
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer2011 · 218 citations
  2. 2Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors2009 · 118 citations
  3. 3Anti-Mullerian Hormone as a Predictor of Time to Menopause in Late Reproductive Age Women2012 · 279 citations
  4. 4A Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause2011 · 461 citations
  5. 5Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation2004 · 193 citations